Viracta Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIRX research report →
About the company
Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials.
- CEO
- Craig R. Jalbert
- IPO
- 2005
- Employees
- 26
- HQ
- Cardiff-by-the-Sea, CA, US
Price Chart
- Market Cap
- $388.70K
- P/E
- -0.01
- P/S
- 0.00
- P/B
- 0.02
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -128.57%
- ROIC
- -115.54%
- Revenue
- $0 · 0.00%
- Net Income
- $-51,058,000 · -2.58%
- EPS
- $-1.32 · 0.00%
- Op Income
- $-50,693,000
- FCF YoY
- -12.75%
- 52W High
- $0.19
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.28
- Avg Volume
- 281.45K
Get TickerSpark's AI analysis on VIRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | ROYSTON IVOR | other | 25,219 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Nov 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | ROYSTON IVOR | other | 25,219 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Aug 25, 24 | Pomerantz Roger | other | 9,034 |
| Jun 20, 24 | ROYSTON IVOR | other | 50,000 |
| Jun 20, 24 | Borellini Flavia | other | 50,000 |
Our VIRX coverage
Recent articles, reports, and earnings notes.
No research on VIRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIRX report →Similar companies
Peers in the same neighborhood.